Delaware
|
001-34079
|
11-3516358
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.0001 per share
|
OCUP
|
NASDAQ
|
Item 5.03 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
Number
|
Exhibit Description
|
|
Third Amendment to Second Amended and Restated Bylaws of Ocuphire Pharma, Inc.
|
||
104
|
Cover Page Interactive Data File (embedded within Inline XBRL document).
|
OCUPHIRE PHARMA, INC.
|
||
By:
|
/s/ Richard Rodgers
|
|
Richard Rodgers
|
||
Interim President and Chief Executive Officer
|
||
Date: June 2, 2023
|
|
/s/Bernhard Hoffmann |
|
Bernhard Hoffmann
|
|
Secretary |